Dysfunction of a 21-mm aortic bioprosthesis treated with percutaneous implantation of a CoreValve prosthesis

J Cardiovasc Med (Hagerstown). 2013 Jul;14(7):541-4. doi: 10.2459/JCM.0b013e328335fa67.

Abstract

Percutaneous aortic valve replacement is an emerging alternative for high surgical risk patients with native aortic valve stenosis. We describe for the first time a valve-in-valve procedure with a CoreValve prosthesis for the treatment of a severely stenotic degenerated aortic bioprosthesis.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Aortic Valve / pathology
  • Aortic Valve / surgery
  • Aortic Valve Stenosis / diagnosis
  • Aortic Valve Stenosis / drug therapy
  • Aortic Valve Stenosis / surgery*
  • Aspirin / administration & dosage
  • Calcinosis / diagnosis
  • Calcinosis / drug therapy
  • Calcinosis / surgery
  • Clopidogrel
  • Combined Modality Therapy
  • Echocardiography
  • Echocardiography, Transesophageal
  • Female
  • Follow-Up Studies
  • Heart Valve Prosthesis Implantation / methods*
  • Humans
  • Platelet Aggregation Inhibitors / administration & dosage
  • Prosthesis Failure
  • Risk Factors
  • Ticlopidine / administration & dosage
  • Ticlopidine / analogs & derivatives
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticlopidine
  • Aspirin

Supplementary concepts

  • Aortic Valve, Calcification of